Evidence map›Paper›PMID 24184050›Full record

ArticleExperimental neurology2013

The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism.

Patricia K Sonsalla, Christal Coleman, Lai-Yoong Wong, Suzan L Harris, Jason R Richardson, Bharathi S Gadad, Wenhao Li, Dwight C German

Open access · hybridAbstract read
In one paragraph

Article in Experimental neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 75 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Association of COVID-19 with Comorbidities: An Update.ACS pharmacology & translational science · 2023
    Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Recent Advances in the Endogenous Brain Renin-Angiotensin System and Drugs Acting on It.Journal of the renin-angiotensin-aldosterone system : JRAAS · 2021
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Patricia K SonsallaDepartment of Neurology, Rutgers, The State University of New Jersey, Robert Wood Johnson Medical School, Piscataway, NJ, USA. Electronic address: sonsalla@rwjms.rutgers.edu.
Christal Coleman
Lai-Yoong Wong
Suzan L Harris
Jason R Richardson
Bharathi S Gadad
Wenhao Li
Dwight C German
Rutgers, The State University of New Jersey · USThe University of Texas Southwestern Medical Center · US

Funding

Translational Research Support CoreP30ES005022 · NIEHS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI ROBERT John LAUMBACH · 1988 to 2026
$47.4M
Adenosine, Glutamate and NeurodegenerationR01NS052733 · NINDS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI SONSALLA, PATRICIA K · 2005 to 2008
$1.0M
Angiotensin and NeurodegenerationR21NS058329 · NINDS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI SONSALLA, PATRICIA K · 2008 to 2009
$375k
NIEHS NIH HHS P30 ES005022NIEHS NIH HHS P30ES005022NINDS NIH HHS R01 NS052733NINDS NIH HHS R21 NS058329NINDS NIH HHS R21NS058329
6 · The paper itself

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by a prominent loss of nigrostriatal dopamine (DA) neurons with an accompanying neuroinflammation. The peptide angiotensin II (AngII) plays a role in oxidative-stress induced disorders and is thought to mediate its detrimental actions via activation of AngII AT1 receptors. The brain renin-angiotensin system is implicated in neurodegenerative disorders including PD. Blockade of the angiotensin converting enzyme or AT1 receptors provides protection in acute animal models of parkinsonism. We demonstrate here that treatment of mice with the angiotensin converting enzyme inhibitor captopril protects the striatum from acutely administered 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrine (MPTP), and that chronic captopril protects the nigral DA cell bodies from degeneration in a progressive rat model of parkinsonism created by the chronic intracerebral infusion of 1-methyl-4-phenylpyridinium (MPP+). The accompanying activation of microglia in the substantia nigra of MPP+-treated rats was reduced by the chronic captopril treatment. These findings indicate that captopril is neuroprotective for nigrostriatal DA neurons in both acute and chronic rodent PD models. Targeting the brain AngII pathway may be a feasible approach to slowing neurodegeneration in PD.

Indexed as

Angiotensin-Converting Enzyme InhibitorsAnimalsBrainCaptoprilDopaminergic NeuronsImmunohistochemistryMaleMiceMPTP PoisoningNerve DegenerationNeuroprotective AgentsRatsAngiotensin-Converting Enzyme InhibitorsCaptoprilNeuroprotective AgentsAngiotensin converting enzymeCaptoprilDopamine neurodegenerationMiceMicrogliaMPP+MPTPOsmotic minipumpParkinson's diseaseRats

Identifiers

PMID24184050
PMCPMC3889207
OpenAlexW2044266198

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.